ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets
5 October 2018 -

ANI Pharmaceuticals Inc (Nasdaq: ANIP), an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, yesterday announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg and 32mg/25mg, an authorized generic of Atacand HCT.

The product is indicated for the treatment of hypertension.

Arthur S Przybyl, ANI's president and CEO, said, 'We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT. This launch represents ANI's sixth generic new product introduction in 2018.'